Precision Targeting Using RNA

Our Mission
At WiNK Therapeutics, we are committed to transforming lives through the development of groundbreaking treatments for Type 1 Diabetes (T1D) and solid tumors, powered by our innovative modified RNA aptamer platform. Our mission is rooted in bold science, compassion, and an unwavering pursuit of cures. We stand with the T1D community, dedicating our research and resources to accelerating the discovery of a cure and improving the lives of individuals and families affected by this chronic condition. In parallel, we are advancing next-generation therapies for solid tumors—targeting some of the most urgent challenges in cancer care. Through collaboration with leading experts and institutions, WiNK is forging a future where Type 1 Diabetes is no longer a lifelong burden and patients battling solid tumors have safer, more effective treatment options and renewed hope.